title: [Prophylaxis against Chagas disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
abstract: Chagas disease is a zoonosis caused by T. cruzi. The estimated prevalence in endemic areas is 0.6-0.9 / 100,000. In immunocompromised behaves as an opportunistic pathogen highly aggressive and can evolve with meningoencephalitis, myocarditis or systemic disease. We recommend obtaining serology for all donor and recipient of SOT and HSCT. An infected donor should be discarded as such. In the case of D (-) R (+) exists controversy between prophylaxis and pre emptive therapy. The chosen drug for prophylaxis is nifurtimox for 3 months, effective but with relevant adverse effects. Monitoring should be done with RPC and MicroStrout weekly until six months post-transplant, then on a monthly basis for the duration of immunosuppression and continued for life clinical monitoring (C3).
authors.affiliation: Servicio de Medicina, Hospital DIPRECA, Santiago. rbenitez1968@gmail.com
authors.forename: Rosana
authors.initials: R
authors.lastname: Benítez
authors.forename: Isabel
authors.initials: I
authors.lastname: Noemí
authors.forename: Renzo
authors.initials: R
authors.lastname: Tassara
authors.forename: Paula
authors.initials: P
authors.lastname: Catalán
authors.forename: Carmen L
authors.initials: CL
authors.lastname: Avilés
mesh_terms: D000328:Adult; D014355:Chagas Disease / Q000469:parasitology / Q000517:prevention & control*; D002648:Child; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D009547:Nifurtimox / Q000008:administration & dosage / Q000627:therapeutic use*; D016377:Organ Transplantation; D011183:Postoperative Complications; D017410:Practice Guidelines as Topic; D033581:Stem Cell Transplantation; D014344:Trypanocidal Agents / Q000627:therapeutic use*
chemical_list: D014344:Trypanocidal Agents; D009547:Nifurtimox